SIGNABLOK

SignaBlok, Inc. is a biopharmaceutical company founded in 2009 to develop novel mechanism-based targeted therapeutics and delivery nanosystems through the use of our revolutionary science and technologies... SignaBlok's elegant approach for modulating cell response is to disrupt functional coupling between two aspects of cell receptor machinery: recognition and signaling. This innovation represents a breakthrough to the modulation of receptor signaling, one of the most effective ways of preventing and treating human disease.

Also known as: SignaBlok, Inc.

Primary location: Shrewsbury United States